Kim 2013.

Methods	4‐Week wash‐out period 8‐Week before‐and‐after study
Participants	Eligible patients were men and women aged 20 to 79 years with documented primary hypercholesterolaemia; LDL‐C > 100 mg/dL Exclusion criteria: therapy with other investigational drugs within 30 days of randomisation, statin hypersensitivity, uncontrolled hypertension, poorly controlled diabetes mellitus, unstable angina, new‐onset MI, creatinine > 2.5 mg/dL, ALT > 2 × ULN, AST > 2 × ULN, CK 2 × ULN, history of malignancy or psychosis, chronic liver disease, drug or alcohol abuse, women who could become pregnant, HRT Atorvastatin 20 mg/d baseline TC: 5.875 mmol/L (227 mg/dL) Atorvastatin 20 mg/d baseline LDL‐C: 4.03 mmol/L (156 mg/dL) Atorvastatin 20 mg/d baseline HDL‐C: 1.24 mmol/L (48 mg/dL) Atorvastatin 20 mg/d baseline TG: 1.74 mmol/L (154 mg/dL)
Interventions	Atorvastatin 20 mg/d
Outcomes	Per cent change from baseline at 8 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	Unclear risk	Dong‐A Pharmaceutical Company Co, Ltd, sponsored the study